Loading stock data…
$0.46-0.01 (-2.11%)
Caribou Biosciences, Inc.
Caribou Biosciences, Inc. in the Healthcare sector is trading at $0.45 with a market capitalization of $49M. Wall Street consensus targets $5.75 (4 analysts), implying a +1164.6% move over the next 12 months. The stock is currently near its 52-week low of $0.44, remaining 73.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 8 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.50M↓ | $2.40M↓ | $3.94M↑ | $2.20M↓ | $2.67M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$25.34M↑ | -$26.28M↑ | -$28.45M↑ | -$29.40M↑ | -$35.43M |
| Net Income | -$24.28M↑ | -$25.09M↑ | -$26.49M↑ | -$27.55M↑ | -$54.10M |
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editin...